Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (451)	2/23/2005 9:52:28 PM
From: quidditch	Respond to of 946

Thanks, Peter. And the fact that so many of the patients in the multi-center trials live, and are being treated, outside the US. Why did this arise? As I recall, there was some issue with [edit] sufficiency of PS 2 patients that could be found in the US, and there being some question whether the patients outside the US centers were accurately classified as PS 2. Why should there not be a host of PS 2 patients with this disease in the US [edit] and who have been treated with taxol and carboplatin? Or is that the rub, that they could not previously have been treated with the comparator drugs? Can there be an inherent integrity issue with non-US investigators? Or at least with those whose responsibility it is to recruit and classify patients for the Stellar 3 trial? quid